Cost Effectiveness of Modified Fractionation Radiotherapy versus Conventional Radiotherapy for Unresected Non-Small-Cell Lung Cancer Patients

被引:17
作者
Ramaekers, Bram L. T. [1 ,2 ]
Joore, Manuela A. [1 ,2 ]
Lueza, Beranger [3 ]
Bonastre, Julia [3 ]
Mauguen, Audrey [3 ]
Pignon, Jean-Pierre [3 ]
Le Pechoux, Cecile [4 ]
De Ruysscher, Dirk K. M. [5 ,6 ]
Grutters, Janneke P. C. [7 ]
机构
[1] Maastricht Univ, CAPHRI Sch Publ Hlth & Primary Care, Dept Hlth Serv Res, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment KEMT, NL-6202 AZ Maastricht, Netherlands
[3] Gustave Roussy, Serv Biostat & Epidemiol, Villejuif, France
[4] Gustave Roussy, Dept Oncol & Radiotherapie, Villejuif, France
[5] Maastricht Univ, Med Ctr, Dept Radiat Oncol MAASTRO, GROW Sch Oncol & Dev Biol, NL-6202 AZ Maastricht, Netherlands
[6] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Radiat Oncol, Louvain, Belgium
[7] Univ Med Ctr, Dept Epidemiol Biostat & HTA, Nijmegen, Netherlands
关键词
Radiotherapy; Dose fractionation; Non-small-cell lung cancer; Cost-benefit analysis; Markov chain; DOSE-ESCALATION TRIAL; CONCURRENT CHEMORADIATION; ACCELERATED RADIOTHERAPY; ECONOMIC-EVALUATION; TUMOR-CONTROL; PHASE-III; HETEROGENEITY; METAANALYSIS; SURVIVAL;
D O I
10.1097/JTO.0b013e31829f6c55
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Modified fractionation radiotherapy (RT), delivering multiple fractions per day or shortening the overall treatment time, improves overall survival for non -small-cell lung cancer (NSCLC) patients compared with conventional fractionation RT (CRT). However, its cost effectiveness is unknown. Therefore, we aimed to examine and compare the cost effectiveness of different modified RT schemes and CRT in the curative treatment of unresected NSCLC patients. Methods: A probabilistic Markov model was developed based on individual patient data from the meta-analysis of radiotherapy in lung cancer (N = 2000). Dutch health care costs, quality-adjusted life years (QALYs), and net monetary benefits (NMBs) were compared between two accelerated schemes (very accelerated RT [VART] and moderately accelerated RT [MART]), two hyperfractionated schemes (using an identical (HRTI) or higher (HRTH) total treatment dose than CRT) and CRT. Results: All modified fractionations were more effective and costlier than CRT (1.12 QALYs, Euro24,360). VART and MART were most effective (1.30 and 1.32 QALYs) and cost Euro25,746 and Euro26,208, respectively. HRTI and HRTH yielded less QALYs than the accelerated schemes (1.27 and 1.14 QALYs), and cost Euro26,199 and Euro29,683, respectively. MART had the highest NMB (Euro79,322; 95% confidence interval [CI], Euro35,478-Euro133,648) and was the most cost-effective treatment followed by VART (Euro78,347; 95% CI, Euro64,635-Euro92,526). CRT had an NMB of Euro65,125 (95% CI, Euro54,663-Euro75,537). MART had the highest probability of being cost effective (43%), followed by VART (31%), HRTI (24%), HRTH (2%), and CRT (0%). Conclusion: Implementing accelerated RT is almost certainly more efficient than current practice CRT and should be recommended as standard RT for the curative treatment of unresected NSCLC patients not receiving concurrent chemo-radiotherapy.
引用
收藏
页码:1295 / 1307
页数:13
相关论文
共 38 条
[1]  
[Anonymous], 2006, Decision modelling for health economic evaluation
[2]  
[Anonymous], 2006, SENS SUST CAR
[3]   Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non-Small-Cell Lung Cancer [J].
Auperin, Anne ;
Le Pechoux, Cecile ;
Rolland, Estelle ;
Curran, Walter J. ;
Furuse, Kiyoyuki ;
Fournel, Pierre ;
Belderbos, Jose ;
Clamon, Gerald ;
Ulutin, Hakki Cuneyt ;
Paulus, Rebecca ;
Yamanaka, Takeharu ;
Bozonnat, Marie-Cecile ;
Uitterhoeve, Apollonia ;
Wang, Xiaofei ;
Stewart, Lesley ;
Arriagada, Rodrigo ;
Burdett, Sarah ;
Pignon, Jean-Pierre .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2181-2190
[4]   Value of information on preference heterogeneity and individualized care [J].
Basu, Anirban ;
Meltzer, David .
MEDICAL DECISION MAKING, 2007, 27 (02) :112-127
[5]   Randomised trial of sequential versus concurrent chemo-radiotherapy in patients with inoperable non-small cell lung cancer (EORTC 08972-22973) [J].
Belderbos, Jose ;
Uitterhoeve, Lon ;
van Zandwijk, Nico ;
Belderbos, Huub ;
Rodrigus, Patrick ;
van de Vaart, Paul ;
Belderbos, Huub ;
Rodrigus, Patrick ;
van de Vaart, Paul ;
Price, Allan ;
van Walree, Nico ;
Legrand, Catherine ;
Dussenneh, Sonia ;
Bartelink, Harry ;
Giaccone, Giuseppe ;
Koning, Caro .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (01) :114-121
[6]   Final results of a Phase I/II dose escalation trial in non-small-cell lung cancer using three-dimensional conformal radiotherapy [J].
Belderbos, Jose S. A. ;
Heemsbergen, Wilma D. ;
De Jaeger, Katrien ;
Baas, Paul ;
Lebesque, Joos V. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (01) :126-134
[7]   Definitive chemoradiation for the treatment of locally advanced non-small-cell lung cancer [J].
Blackstock, A. William ;
Govindan, Ramaswamy .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (26) :4146-4152
[8]  
Bradley JD, 2011, RANDOMIZED PHASE 3 C
[9]   The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials [J].
Bucher, HC ;
Guyatt, GH ;
Griffith, LE ;
Walter, SD .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1997, 50 (06) :683-691
[10]  
Buyse M, 2000, ONCOLOGY-NY, V14, P437